Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzodiazepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzodiazepine SCHEMBL5739614 | 1.00 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL8124489 | 0.98 | GAA (0.41) | GAAMAPT | |
| Benzodiazepine SCHEMBL4697172 | 0.98 | GAA (0.41) | GAAMAPT | |
| Benzodiazepine SCHEMBL4703020 | 0.98 | GAA (0.41) | GAAMAPT | |
| Benzodiazepine SCHEMBL7160172 | 0.98 | GAA (0.44) | GAAMAPT | |
| Benzodiazepine SCHEMBL8137 | 0.98 | GAA (0.44) | GAAMAPT | |
| Benzodiazepine SCHEMBL11484022 | 0.96 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL8139617 | 0.96 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL4144041 | 0.96 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL988773 | 0.96 | GAA (0.43) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118159270-A | Apical sodium-dependent transporter inhibitor compositions | 米鲁姆制药公司 | 2024-06-07 | — | — | CN | claimed |
| CN-116745293-A | Salts and crystals | 金奥克斯治疗有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-115201349-A | GC analysis method for content of key reagent propionaldehyde and the like in olanzapine starting material | 北京万全德众医药生物技术有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-114555166-A | Stimulation of neuronal plasticity | 奥地利科学技术研究所 | 2022-05-27 | — | — | CN | claimed |
| CN-106640793-B | Hydraulic station device and its method of work are supplied in a kind of carbon tetrachloride processing | 徐州工程学院 | 2017-12-29 | — | — | CN | claimed |
| CN-106640793-A | Supply hydraulic station device for carbon tetrachloride treatment and operating method thereof | 徐州工程学院 | 2017-05-10 | — | — | CN | claimed |
| CN-102838619-B | Olanzapine intermediate and method for preparing olanzapine using same | SICHUAN BAICAO BIOLOGICAL PHARMACEUTICAL CO., LTD. (CN) | 2014-10-15 | — | — | CN | claimed |
| CN-102276624-B | Olanzapine related substance and preparation method as well as high-efficiency liquid-phase chromatographic analysis method thereof | UNIV DALIAN TECH | 2013-10-16 | — | — | CN | claimed |
| CN-102276592-B | Related substance of olanzapine and preparation method and analytical method thereof | UNIV DALIAN TECH | 2013-10-16 | — | — | CN | claimed |
| CN-102838619-A | Olanzapine intermediate and method for preparing olanzapine using same | SICHUAN BAICAO BIOLOG PHARMACEUTICAL CO LTD | 2012-12-26 | — | — | CN | claimed |
| CN-102276592-A | Related substance of olanzapine and preparation method and analytical method thereof | — | 2011-12-14 | — | — | CN | claimed |
| CN-102276624-A | Olanzapine related substance and preparation method as well as high-efficiency liquid-phase chromatographic analysis method thereof | — | 2011-12-14 | — | — | CN | claimed |
| EP-1963335-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | claimed |
| CN-101084222-A | Synthesis of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2, 3-b][1,5]benzodiazepine and salts thereof | LEK PHARMACEUTICALS (SI) | 2007-12-05 | — | — | CN | claimed |
| WO-2007054750-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2007-05-18 | — | — | WO | claimed |
| WO-2005107375-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE FORM-I | MATRIX LABORATORIES LTD (IN) | 2005-11-17 | — | — | WO | claimed |
| EP-1509531-A1 | METHODS FOR PREPARATION OF OLANZAPINE POLYMORPHIC FORM I | INSTYTUT FARMACEUTYCZNY (PL) | 2005-03-02 | — | — | EP | claimed |
| CN-1466588-A | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine | 雷迪实验室有限公司 | 2004-01-07 | — | — | CN | claimed |
| WO-2003097650-A1 | METHODS FOR PREPARATION OF OLANZAPINE POLYMORPHIC FORM I | INSTITUT FARMACEUTYCZNY (PL) | 2003-11-27 | — | — | WO | claimed |
| CN-119285474-A | Synthesis method of 3,3', 4' -tetraminobiphenyl | 大连新阳光材料科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118159270-A | Apical sodium-dependent transporter inhibitor compositions | 米鲁姆制药公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-115232132-B | Midazolam hydrochloride G crystal form and preparation method thereof | 福安药业集团重庆礼邦药物开发有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4271347-A1 | MEDICINAL PRODUCT COMPRISING A FLEXIBLE PLASTIC BAG AND AN AQUEOUS, READY-TO-USE SOLUTION OF MIDAZOLAM | B. Braun Melsungen AG (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230329971-A1 | MEDICINAL PRODUCT COMPRISING A FLEXIBLE PLASTIC BAG AND AN AQUEOUS, READY-TO-USE SOLUTION OF MIDAZOLAM | B. BRAUN MELSUNGEN AG (DE) | 2023-10-19 | — | — | US | disclosed |
| US-11708368-B2 | Crystal form of ethyl (S)-3-(8-bromo-1-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl)propanoate hydrochloride | JIANGSU NHWALUOKANG PHARMACEUTICAL RESEARCH AND DEVELOPMENT CO., LTD. (CN) | 2023-07-25 | — | — | US | disclosed |
| CN-116041351-A | Novel midazolam hydrochloride crystal form and preparation method thereof | 成都硕德药业有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115232132-A | Midazolam hydrochloride G crystal form and preparation method thereof | 福安药业集团重庆礼邦药物开发有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115201349-A | GC analysis method for content of key reagent propionaldehyde and the like in olanzapine starting material | 北京万全德众医药生物技术有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220265666-A1 | METHODS OF TREATING SUBSTANCE ABUSE DISORDER, DYSPNEA, TINNITUS, AND CHILD AND ADOLESCENT DEPRESSION | PRAXIS PREC MEDICINES INC (US) | 2022-08-25 | — | — | US | disclosed |
| WO-2022144276-A1 | MEDICINAL PRODUCT COMPRISING A FLEXIBLE PLASTIC BAG AND AN AQUEOUS, READY-TO-USE SOLUTION OF MIDAZOLAM | B. BRAUN MELSUNGEN AG (DE) | 2022-07-07 | — | — | WO | disclosed |
| EP-4023202-A1 | MEDICINAL PRODUCT COMPRISING A FLEXIBLE PLASTIC BAG AND AN AQUEOUS, READY-TO-USE SOLUTION OF MIDAZOLAM | B. Braun Melsungen AG (DE) | 2022-07-06 | — | — | EP | disclosed |
| US-11246801-B2 | Infusion bag of midazolam for intravenous use | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2022-02-15 | — | — | US | disclosed |
| US-20210401669-A9 | INFUSION BAG OF MIDAZOLAM FOR INTRAVENOUS USE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2021-12-30 | — | — | US | disclosed |
| US-20210369565-A9 | INFUSION BAG OF MIDAZOLAM FOR INTRAVENOUS USE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2021-12-02 | — | — | US | disclosed |
| CN-113543769-A | Infusion bag for midazolam for intravenous use | 太阳医药工业有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210002283-A1 | Benzodiazepine Derivative Hydrochloride and Crystal Form, Preparation Method and Application thereof | JIANGSU NHWALUOKANG PHARMACEUTICAL RESEARCH AND DEVELOPMENT CO., LTD. (CN) | 2021-01-07 | — | — | US | disclosed |
| EP-3753940-A1 | BENZODIAZEPINE DERIVATIVE HYDROCHLORIDE AND CRYSTAL FORM, PREPARATION METHOD, AND APPLICATION THEREOF | Jiangsu Nhwaluokang Pharmaceutical Research and Development Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| CN-112110935-A | Preparation method of olanzapine crystal form II | 北京万全德众医药生物技术有限公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20200315913-A1 | INFUSION BAG OF MIDAZOLAM FOR INTRAVENOUS USE | SUN PHARMACEUTICAL IND LTD (IN) | 2020-10-08 | — | — | US | disclosed |
| CN-111712501-A | Benzodiazepine derivative hydrochloride, crystal form, preparation method and application thereof | 江苏恩华络康药物研发有限公司 | 2020-09-25 | — | — | CN | disclosed |
| US-20200268606-A1 | INFUSION BAG OF MIDAZOLAM FOR INTRAVENOUS USE | SUN PHARMACEUTICAL IND LTD (IN) | 2020-08-27 | — | — | US | disclosed |
| CN-106640793-B | Hydraulic station device and its method of work are supplied in a kind of carbon tetrachloride processing | 徐州工程学院 | 2017-12-29 | — | — | CN | disclosed |
| CN-106640793-A | Supply hydraulic station device for carbon tetrachloride treatment and operating method thereof | 徐州工程学院 | 2017-05-10 | — | — | CN | disclosed |
| CN-102838619-B | Olanzapine intermediate and method for preparing olanzapine using same | SICHUAN BAICAO BIOLOGICAL PHARMACEUTICAL CO., LTD. (CN) | 2014-10-15 | — | — | CN | disclosed |
| CN-102838619-B | Olanzapine intermediate and method for preparing olanzapine using same | SICHUAN BAICAO BIOLOGICAL PHARMACEUTICAL CO., LTD. (CN) | 2014-10-15 | — | — | CN | disclosed |
| EP-2264016-B1 | A process for producing pure form form of 2-Methyl-4-(4-Methyl-1-Piperazinyl)-10h-thieno[2,3-B][1,5] benzodiazepine | JUBILANT ORGANOSYS LTD (IN) | 2013-05-01 | — | — | EP | disclosed |
| CN-102838619-A | Olanzapine intermediate and method for preparing olanzapine using same | SICHUAN BAICAO BIOLOG PHARMACEUTICAL CO LTD | 2012-12-26 | — | — | CN | disclosed |
| CN-102838619-A | Olanzapine intermediate and method for preparing olanzapine using same | SICHUAN BAICAO BIOLOG PHARMACEUTICAL CO LTD | 2012-12-26 | — | — | CN | disclosed |
| CN-102268010-A | Preparation method and refining method of olanzapine | — | 2011-12-07 | — | — | CN | disclosed |
| EP-2356123-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | F. Hoffmann-La Roche AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| EP-1513846-B1 | PROCESS OF PREPARATION OF OLANZAPINE FORM I | SANDOZ AG (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011009831-A1 | PROCESS FOR THE PURIFICATION OF OLANZAPINE | LEK PHARMACEUTICALS D.D. (SI) | 2011-01-27 | — | — | WO | disclosed |
| EP-2264016-A2 | A process for producing pure form form of 2-Methyl-4-(4-Methyl-1-Piperazinyl)-10h-thieno[2,3-B][1,5] benzodiazepine | Jubilant Organosys Limited (IN) | 2010-12-22 | — | — | EP | disclosed |
| CN-101168544-B | Technique for preparing olanzapine | SOUTHWEST SYNTHETIC PHARMACEUTICAL CORP LTD | 2010-11-17 | — | — | CN | disclosed |
| US-7834176-B2 | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E | SANDOZ AG (CH) | 2010-11-16 | — | — | US | disclosed |
| WO-2010054961-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
| CN-101400683-A | Process for the preparation of olanzapine | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2009-04-01 | — | — | CN | disclosed |
| EP-1778649-A4 | A PROCESS FOR PRODUCING PURE FORM OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-b][1,5]BENZODIAZEPINE | JUBILANT ORGANOSYS LTD (IN) | 2008-09-10 | — | — | EP | disclosed |
| EP-1963335-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | disclosed |
| EP-1963335-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| CN-101168544-A | Technique for preparing olanzapine | SOUTHWEST SYNTHETIC PHARMACEUT (CN) | 2008-04-30 | — | — | CN | disclosed |
| CN-101084222-A | Synthesis of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2, 3-b][1,5]benzodiazepine and salts thereof | LEK PHARMACEUTICALS (SI) | 2007-12-05 | — | — | CN | disclosed |
| CN-101061124-A | A process for the preparation of n-demethylolanzapine | ADAMED SP ZOO (PL) | 2007-10-24 | — | — | CN | disclosed |
| WO-2007054750-A3 | PROCESS FOR THE PREPARATION OF OLANZAPINE | EGIS GYOGYSZERGYAR NYRT (HU) | 2007-10-11 | — | — | WO | disclosed |
| CN-100338069-C | Process for the preparation of olanzapine and an intermediate therefor | ADAMED SP ZOO (PL) | 2007-09-19 | — | — | CN | disclosed |
| WO-2007102167-A1 | A PROCESS FOR THE PREPARATION OF ANHYDROUS POLYMORPHIC FORM OF OLANZAPINE | LEE PHARMA LIMITED (IN) | 2007-09-13 | — | — | WO | disclosed |
| US-20070173496-A1 | Novel polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E | SANDOZ AG (CH) | 2007-07-26 | — | — | US | disclosed |
| EP-1442040-B1 | BRIDGED BICYCLE (1,4) BENZODIAZEPINE VASOPRESSIN RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2007054750-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007054750-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2007-05-18 | — | — | WO | disclosed |
| EP-1781665-A2 | OLANZAPINE SALTS AND THEIR CONVERSION TO OLANZAPINE FREE BASE | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2007-05-09 | — | — | EP | disclosed |
| EP-1778649-A1 | A PROCESS FOR PRODUCING PURE FORM OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-b][1,5]BENZODIAZEPINE | Jubilant Organosys Limited (IN) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| CN-1923834-A | Intermediate of olanzapine, preparation and application thereof | HANGZHOU SHENGMEI MEDICINE TEC (CN) | 2007-03-07 | — | — | CN | disclosed |
| EP-1749010-A2 | SYNTHESIS OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO 2, 3-B 1,5 BENZODIAZEPINE AND SALTS THEREOF | LEK Pharmaceuticals D.D. (SI) | 2007-02-07 | — | — | EP | disclosed |
| EP-1730153-A1 | ISOPROPANOL WATER SOLVATE OF OLANZAPINE | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2006-12-13 | — | — | EP | disclosed |
| CN-1285594-C | Diazacycloalkanes as oxytocin agonists | FERRING BV (NL) | 2006-11-22 | — | — | CN | disclosed |
| EP-1716154-A1 | PROCESS FOR THE PREPARATION OF OLANZAPINE FORM 1 USEFUL AS ANTIPSYCHOTIC DRUG | Neuland Laboratories Ltd (IN) | 2006-11-02 | — | — | EP | disclosed |
| CN-1273469-C | Tricyclic diazepines as tocolytic oxytocin receptor antagonists | WYETH CORP (US) | 2006-09-06 | — | — | CN | disclosed |
| WO-2005107375-A3 | PROCESS FOR THE PREPARATION OF OLANZAPINE FORM-I | MATRIX LAB LTD (IN) | 2006-04-06 | — | — | WO | disclosed |
| CN-1747938-A | Novel substituted 2, 3-benzodiazepine * derivatives | IVAX INST FOR DRUG RES LTD (HU) | 2006-03-15 | — | — | CN | disclosed |
| WO-2006025065-A1 | A PROCESS FOR THE PREPARATION OF ANHYDROUS OLANZOPINE HYDROCHLORIDE OF FORM-1 | LEE PHARMA PRIVATE LIMITED (IN) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006010620-A2 | OLANZAPINE SALTS AND THEIR CONVERSION TO OLANZAPINE FREE BASE | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006006180-A1 | A PROCESS FOR PRODUCING PURE FORM OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-b][1,5]BENZODIAZEPINE | JUBILANT ORGANOSYS LIMITED (IN) | 2006-01-19 | — | — | WO | disclosed |
| CN-1233646-C | Process of 2-methyl-thiophene benzodinitro heterotropilidene | HWASHENG PHARMACEUTICAL CORP (US) | 2005-12-28 | — | — | CN | disclosed |
| WO-2005107375-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE FORM-I | MATRIX LABORATORIES LTD (IN) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005107375-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE FORM-I | MATRIX LABORATORIES LTD (IN) | 2005-11-17 | — | — | WO | disclosed |
| EP-1592693-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | Ferring B.V. (NL) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005090359-A2 | SYNTHESIS OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2, 3-B][1,5]BENZODIAZEPINE AND SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005085256-A1 | ISOPROPANOL WATER SOLVATE OF OLANZAPINE | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005080401-A1 | PROCESS FOR THE PREPARATION OF OLANZAPINE FORM 1 USEFUL AS ANTIPSYCHOTIC DRUG | NEULAND LABORATORIES LIMITED (IN) | 2005-09-01 | — | — | WO | disclosed |
| CN-1662543-A | Process for the preparation of olanzapine and an intermediate therefor | ADAMED SP ZOO (PL) | 2005-08-31 | — | — | CN | disclosed |
| US-6936604-B2 | Bridged bicyclic amino acid-derived [1,4]benzodiazepine vasopressin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| CN-1608068-A | Bridged bicyclic amino acid-derived [1,4]benzodiazepine vasopressin receptor antagonists | ORTHO MCNEIL PHARM INC (US) | 2005-04-20 | — | — | CN | disclosed |
| EP-1509531-A1 | METHODS FOR PREPARATION OF OLANZAPINE POLYMORPHIC FORM I | INSTYTUT FARMACEUTYCZNY (PL) | 2005-03-02 | — | — | EP | disclosed |
| CN-1543467-A | Diazacycloalkanes as oxytocin agonists | — | 2004-11-03 | — | — | CN | disclosed |
| CN-1532199-A | Process of 2-methyl-thiophene benzodinitro heterotropilidene | 华生制药公司 | 2004-09-29 | — | — | CN | disclosed |
| CN-1531537-A | Novel tricyclic pyridyl benzazepine * carboxamides and derivatives thereof useful as tocolytic oxytocin receptor antagonists | — | 2004-09-22 | — | — | CN | disclosed |
| WO-2004072083-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | FERRING B.V. (NL) | 2004-08-26 | — | — | WO | disclosed |
| CN-1501932-A | Tricyclic diazepines * as oxytocin receptor antagonists for tocolysis | — | 2004-06-02 | — | — | CN | disclosed |
| CN-1501931-A | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | — | 2004-06-02 | — | — | CN | disclosed |
| US-20040067936-A1 | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine | REDDY'S LABORATORIES LIMITED (IN) | 2004-04-08 | — | — | US | disclosed |
| WO-2002083683-A9 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-1377581-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| CN-1466588-A | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine | 雷迪实验室有限公司 | 2004-01-07 | — | — | CN | disclosed |
| CN-1462269-A | Fused azepine drivatives and their use as antidiuretic agents | FERRING BV (NL) | 2003-12-17 | — | — | CN | disclosed |
| WO-2003097650-A1 | METHODS FOR PREPARATION OF OLANZAPINE POLYMORPHIC FORM I | INSTITUT FARMACEUTYCZNY (PL) | 2003-11-27 | — | — | WO | disclosed |
| US-20030119822-A1 | Bridged bicyclic amino acid-derived [1,4]benzodiazepine vasopressin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-26 | — | — | US | disclosed |
| CN-1096464-C | 2, 3-benzodiazepine * derivatives, their preparation and intermediates and their use as pharmaceuticals | SHCERING AG (DE) | 2002-12-18 | — | — | CN | disclosed |
| WO-2002083683-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1061961-A4 | APPARATUSES AND PROCESSES FOR WHOLE-BODY HYPERTHERMIA | VIACIRQ INC (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20010039441-A1 | Apparatuses and processes for whole-body hyperthermia | VIACIRQ, INC. | 2001-11-08 | — | — | US | disclosed |
| EP-1061961-A1 | APPARATUSES AND PROCESSES FOR WHOLE-BODY HYPERTHERMIA | Hemotherm, Inc. (US) | 2000-12-27 | — | — | EP | disclosed |
| CN-1268949-A | Fused thiophene compounds and medical use thereof | YOSHITOMI PHARMACEUTICAL (JP) | 2000-10-04 | — | — | CN | disclosed |
| EP-0987266-A1 | BIPHENYL DERIVATIVES AND MEDICINAL COMPOSITIONS | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999037335-A1 | APPARATUSES AND PROCESSES FOR WHOLE-BODY HYPERTHERMIA | HEMOTHERM, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| US-5929085-A | Amidine and isothiourea derivatives, compositions containing them and their use as inhibitors of nitric oxide synthase | ASTRA AKTIEBOLAG (SE) | 1999-07-27 | — | — | US | disclosed |
| CN-1210538-A | 2, 3-benzodiazepine * derivatives, their preparation and use as medicaments | SHCERING AG (DE) | 1999-03-10 | — | — | CN | disclosed |
| CN-1207098-A | Amidine and isothiourea derivatives as nitric oxide synthase inhibitors | ASTRA AB (SE) | 1999-02-03 | — | — | CN | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0054416-A2 | Benzodiazepine compounds and their use as pharmaceuticals | Lilly Industries Limited (GB) | 1982-06-23 | — | — | EP | disclosed |
| EP-0027390-A1 | Novel benzodiazepine compounds, their preparation, intermediates employed in their preparation, and pharmaceutical compositions containing them | Lilly Industries Limited (GB) | 1981-04-22 | — | — | EP | disclosed |
| EP-0009800-A2 | 4-Phenyl-1,3-benzodiazepines, method for their preparation, pharmaceutical compositions containing them, and the compounds for use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-04-16 | — | — | EP | disclosed |
| US-4192874-A | Substituted 1,2,6,7-tetrahydroindolo[1,7-ab][1,5]benzodiazepines | AMERICAN HOECHST CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
| US-4186199-A | Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines | AMERICAN HOECHST CORPORATION (US) | 1980-01-29 | — | — | US | disclosed |
| US-4082761-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS | THE UPJOHN COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-4082761-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS | THE UPJOHN COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200315913-A1 | INFUSION BAG OF MIDAZOLAM FOR INTRAVENOUS USE | ABCB11, CYP3A5, ABCB1 | GAA 2623/4885MAPT 2382/4885 |
| US-20220265666-A1 | METHODS OF TREATING SUBSTANCE ABUSE DISORDER, DYSPNEA, TINNITUS, AND CHILD AND ADOLESCENT DEPRESSION | SLC6A12, TAAR5, SLC6A4 | GAA 975/4885MAPT 4619/4885 |
| US-20030119822-A1 | Bridged bicyclic amino acid-derived [1,4]benzodiazepine vasopressin receptor antagonists | AVPR1B, AVPR2, AVPR1A | GAA 4629/4885MAPT 2424/4885 |
| US-20210002283-A1 | Benzodiazepine Derivative Hydrochloride and Crystal Form, Preparation Method and Application thereof | GABRA1, GABRA5, GABRA3 | GAA 4483/4885MAPT 584/4885 |
| US-11246801-B2 | Infusion bag of midazolam for intravenous use | ABCB11, CYP3A5, ABCB1 | GAA 2623/4885MAPT 2382/4885 |
| US-11708368-B2 | Crystal form of ethyl (S)-3-(8-bromo-1-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl)propanoate hydrochloride | GABRA1, GABRA3, GABRA6 | GAA 4270/4885MAPT 471/4885 |
| US-20070173496-A1 | Novel polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E | HTR3C, HTR1A, HTR5A | GAA 4492/4885MAPT 627/4885 |
| US-20210401669-A9 | INFUSION BAG OF MIDAZOLAM FOR INTRAVENOUS USE | ABCB11, CYP3A5, ABCB1 | GAA 2623/4885MAPT 2382/4885 |
| US-20200268606-A1 | INFUSION BAG OF MIDAZOLAM FOR INTRAVENOUS USE | ABCB11, CYP3A5, ABCB1 | GAA 2646/4885MAPT 2384/4885 |
| US-20210369565-A9 | INFUSION BAG OF MIDAZOLAM FOR INTRAVENOUS USE | ABCB11, CYP3A5, ABCB1 | GAA 2646/4885MAPT 2384/4885 |
| US-20040067936-A1 | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine | CYP2F1, FIS1, CYP4B1 | GAA 4042/4885MAPT 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.